Ontology highlight
ABSTRACT:
SUBMITTER: Johnson L
PROVIDER: S-EPMC3754254 | biostudies-literature | 2013 Sep
REPOSITORIES: biostudies-literature
Johnson Leisa L Huseni Mahrukh M Smyczek Tanya T Lima Anthony A Yeung Stacey S Cheng Jason H JH Molina Rafael R Kan David D De Mazière Ann A Klumperman Judith J Kasman Ian I Zhang Yin Y Dennis Mark S MS Eastham-Anderson Jeffrey J Jubb Adrian M AM Hwang Olivia O Desai Rupal R Schmidt Maike M Nannini Michelle A MA Barck Kai H KH Carano Richard A D RA Forrest William F WF Song Qinghua Q Chen Daniel S DS Naumovski Louie L Singh Mallika M Ye Weilan W Hegde Priti S PS
The Journal of clinical investigation 20130815 9
Many oncology drugs are administered at their maximally tolerated dose without the knowledge of their optimal efficacious dose range. In this study, we describe a multifaceted approach that integrated preclinical and clinical data to identify the optimal dose for an antiangiogenesis agent, anti-EGFL7. EGFL7 is an extracellular matrix-associated protein expressed in activated endothelium. Recombinant EGFL7 protein supported EC adhesion and protected ECs from stress-induced apoptosis. Anti-EGFL7 a ...[more]